26 citations
,
October 2019 in “JNCI Cancer Spectrum” This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.
6 citations
,
January 2020 in “BMC Neuroscience” In this study, male-derived brain tissue exhibited higher cell death following ischemia compared to female-derived tissue, and certain steroid hormones showed different neuroprotective effects depending on the sex of the tissue.
This study found that DHT induces apoptosis in human keratinocyte cells via ERK activation, independently of androgen receptors and the Wnt/β-catenin pathway.
August 2023 in “Frontiers in Oncology” This review highlights recent advancements in prostate cancer treatments, particularly new drugs targeting signaling pathways and showing promise in clinical trials, but notes the high recurrence rate of castration-resistant cancer post-therapy, requiring ongoing efforts for effective solutions.
1 citations
,
January 2020 In this study, researchers found that cepharanthine significantly inhibited the growth of non-small cell lung cancer cells by inducing apoptosis through ROS generation and altering multiple signaling pathways, suggesting potential as a novel lung cancer treatment.